Abstract 261P
Background
While the expected survival of patients with FL almost reaches that of the normal population, the outcomes of patients who experience early progression within 24 months, that is, POD24 is dismal. Unlike the West, FL is less frequent in Asia as it accounts about 10% of non-Hodgkin’s lymphoma. To define outcomes and treatment patterns FL patients who experienced POD24 in Korea, we performed a multicenter, retrospective analysis.
Methods
The inclusion criteria were as follows, 1) Histologically confirmed diagnosis of FL grade 1, 2, and 3A; 2) Documented POD24. The primary endpoint was OS from the first diagnosis of FL.
Results
Between 2007 to 2019, a total of 73 cases were eligible for analysis. Median age at diagnosis was 53 (range, 28 – 83). All patients were Asians. In terms of FLIPI-1 risk group, 14 (19.2%), 24 (32.9%), and 35 (47.9%) patients were categorized as low-, intermediate-, and high-risk group, respectively. Sixty-two patients (84.9%) had received rituximab as the induction treatment, and 11 patients (15.1%) had not. CVP was the most commonly used regimen (N=40), followed by CHOP (N = 26). Forty-four patients (60.3%) had received maintenance treatment with rituximab and 29 patients (39.7%) had not.
POD24 was documented after a median duration of 11.6 months. Rituximab wad administered in 19 patients, and platinum-based regimens (N = 23) were the most commonly used backbone treatment followed by bendamustine (N = 15) and fludarabine-based regimens (N = 12). PFS from the first progression was 23.7 months. The median OS was 128.9 mo, with the 5-year being 75.2%. OS did not significantly differ by the re-induction regimen, use of rituximab, or SCT.
When we compared these patients to our previous cohort in which 191 FL patients without POD24 were included, the 5-year survival rate was significantly inferior in the current cohort (75.2% vs. 95.7%, p < 0.001).
Conclusions
The 5-year OS rate of our patients with POD24 seems better than Western data, although there are many confounding factors including baseline FLIPI and the induction treatment. As expected, the 5-year OS rate of patient with POD24 was inferior to that of patients without POD24. To best salvage these patients, further studies are warranted to develop effective treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
163P - Gastrointestinal stromal tumours (GIST) in adolescents and young adults (AYA) in an Asian institution from 2002 to 2018
Presenter: Evelyn Yi Ting Wong
Session: e-Poster Display Session
164P - The impact of sarcopenia on chemotherapy toxicity and survival rate among hepatocellular carcinoma patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Elizabeth Marcella
Session: e-Poster Display Session
165P - Prognostic factors in sorafenib-treated hepatocellular carcinoma: Multicentre analysis of a European population sample
Presenter: João Gramaça
Session: e-Poster Display Session
166P - Differences and similarities in presentation and management patterns in patients with hepatocellular carcinoma (HCC) across Hong Kong, Singapore and Thailand
Presenter: Pierce Chow
Session: e-Poster Display Session
167P - Epidemiology of hepatocellular carcinoma (HCC) in tertiary level hospitals in Bangladesh
Presenter: Abdullah Al Mamun Khan
Session: e-Poster Display Session
168P - Response assessments in hepatocellular carcinoma: What are the best criteria to utilize? mRECIST or RECIST 1.1? A retrospective meta-analysis of multiple phase III trials
Presenter: Oliver Bohnsack
Session: e-Poster Display Session
169P - IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCC
Presenter: Masatoshi Kudo
Session: e-Poster Display Session
170P - Sintilimab plus anlotinib as first-line therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC)
Presenter: Xiaofeng Chen
Session: e-Poster Display Session
171P - Transarterial chemoembolization (TACE) plus lenvatinib versus TACE plus sorafenib for hepatocellular carcinoma (HCC) with portal vein tumour thrombus (PVTT): A prospective randomized study
Presenter: Xiaoyan Ding
Session: e-Poster Display Session
172P - Triple combination therapy of lenvatinib, toripalimab, and hepatic arterial infusion chemotherapy versus lenvatinib for advanced hepatocellular carcinoma
Presenter: Zhi-Cheng Lai
Session: e-Poster Display Session